Paradi Mirmirani

ORCID: 0000-0001-8627-2995
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hair Growth and Disorders
  • Autoimmune Bullous Skin Diseases
  • Dermatologic Treatments and Research
  • Dermatology and Skin Diseases
  • Autoimmune and Inflammatory Disorders
  • Skin and Cellular Biology Research
  • Nail Diseases and Treatments
  • melanin and skin pigmentation
  • RNA regulation and disease
  • Cutaneous lymphoproliferative disorders research
  • Genetic and rare skin diseases.
  • Body Contouring and Surgery
  • Cancer and Skin Lesions
  • Skin Protection and Aging
  • Dermatological and Skeletal Disorders
  • Eosinophilic Disorders and Syndromes
  • Chemotherapy-related skin toxicity
  • Wound Healing and Treatments
  • T-cell and Retrovirus Studies
  • Skin Diseases and Diabetes
  • Dermatological and COVID-19 studies
  • Herpesvirus Infections and Treatments
  • Biomedical Ethics and Regulation
  • Peroxisome Proliferator-Activated Receptors
  • Inflammatory Myopathies and Dermatomyositis

Kaiser Permanente Vallejo Medical Center
2014-2025

University of California, San Francisco
2012-2024

Case Western Reserve University
2011-2022

Colorado Permanente Medical Group
2021

Health Net
2017

University Hospitals of Cleveland
2003-2017

Atrium Health Wake Forest Baptist
2017

Uniformed Services University of the Health Sciences
2017

North American Hair Research Society
2017

The University of Melbourne
2017

10.1016/j.jisp.2020.05.007 article EN publisher-specific-oa Journal of Investigative Dermatology Symposium Proceedings 2020-10-21

BackgroundJanus kinase (JAK) activation is suggested to have a pathological role in alopecia areata (AA). CTP-543, deuterated compound that selectively inhibits JAK1 and JAK2, being developed as an oral treatment for AA.ObjectiveTo assess the safety efficacy of 24-week regimen CTP-543 patients with chronic, moderate-to-severe AA.MethodsIn this phase 2, randomized, double-blind, placebo-controlled, sequential-design trial, were randomized receive (4 mg, 8 or 12 mg) placebo every hours 24...

10.1016/j.jaad.2022.03.045 article EN cc-by-nc-nd Journal of the American Academy of Dermatology 2022-03-30

Primary cicatricial alopecias (PCAs), rare disorders that lead to permanent hair loss, have been poorly understood and are difficult treat. Lichen planopilaris (LPP)is a prototypical PCA; patients often present with sudden onset of loss clinically significant symptoms itching, burning, pain the scalp. Examination reveals patchy alopecia or more diffuse thinning scalp characteristic perifollicular erythema scale at margins areas alopecia.Treatment typically includes use antiinflammatory...

10.1001/archdermatol.2009.283 article EN Archives of Dermatology 2009-12-01

The role of vitamin D in the proliferation and differentiation keratinocytes is well known within field dermatology.We sought to evaluate that receptor play hair cycle assess how this can be clinically applied treatment disorders.A MEDLINE search (1955-July 2009) was preformed find relevant articles pertaining D, receptor, loss.The independent plays an important cycling, specifically anagen initiation. follicle cycling not as understood.The review broad there are limited human studies...

10.5070/d38s34p6b7 article EN Dermatology Online Journal 2010-02-01

Traction alopecia is hair loss caused by prolonged or repetitive tension on the hair. Diagnostic challenges are encountered when clinical suspicion not high and a history of traction remote obtained. We have made observation that presence retained hairs along frontal and/or temporal rim, which we termed "fringe sign," finding seen in both early late alopecia, may be useful marker condition.This was retrospective single-center review to determine frequency fringe sign patients with...

10.5070/d325m840mz article EN Dermatology Online Journal 2011-11-01

The current classification for alopecia areata (AA) does not provide a consistent assessment of disease severity.To develop an AA severity scale based on expert experience.A modified Delphi process was utilized. An advisory group 22 clinical experts from the United States formed to this scale. Representatives pharmaceutical industry provided feedback during its development.Survey responses were used draft criteria, aspiring simple that may be easily applied in practice. A consensus vote held...

10.1016/j.jaad.2021.08.043 article EN cc-by-nc-nd Journal of the American Academy of Dermatology 2021-08-30

It has long been known that women lose satisfaction with their hair ageing. Our data show caucasian perceive a decrease in amount mid 40s further the to late 50s, which leads this dissatisfaction. Neither loss of density (hairs per cm(2) ) nor shaft diameter alone can fully account for perception. A new metric, 'hair amount', is proposed as quantitative metric combining impact both and on perception loss.Creation single parameter contribution female age-related loss.In total, 1099 (ages...

10.1111/j.1365-2133.2012.11010.x article EN British Journal of Dermatology 2012-04-23

Since the initial description of frontal fibrosing alopecia (FFA) in 1994, increasingly more cases FFA have been reported literature. Although clear epidemiologic data on incidence and prevalence is not available, it intriguing to consider whether should be labeled as an emerging epidemic. A medline trend analysis well literature review using keywords "alopecia," "hair loss," "cicatrical" were performed. Medline published papers from 1905 2016 showed that number publications referenced...

10.1159/000489793 article EN Skin Appendage Disorders 2018-06-19

Beginning in March 2020, case reports and series linked the COVID-19 pandemic with an increased occurrence of chilblains, but this association has not been evaluated epidemiologic study.To assess whether a correlation exists between incidence chilblains incidence.A retrospective cohort study was conducted within Kaiser Permanente Northern California system from January 1, 2016, to December 31, 2020; health plan members all ages were included.COVID-19 207 location-months, representing 23...

10.1001/jamadermatol.2021.2120 article EN JAMA Dermatology 2021-06-23

Abstract Background Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, demonstrated efficacy over 48 weeks in patients with alopecia areata (AA) the ALLEGRO phase 2b/3 study. Objectives This post hoc analysis evaluated individual Severity of Alopecia Tool (SALT) score trajectories who received ritlecitinib 50 mg and rolled from Phase into ongoing, open‐label, 3 ALLEGRO‐LT study to describe long‐term response patterns associated baseline disease characteristics. Methods Patients aged ≥12...

10.1111/jdv.20547 article EN cc-by Journal of the European Academy of Dermatology and Venereology 2025-02-17

10.1067/s0190-9622(03)00873-9 article EN Journal of the American Academy of Dermatology 2003-10-01

Female pattern hair loss is a common problem affecting large number of women worldwide but beset by paucity research. The study androgens has hitherto dominated the field biology there increasing scientific and clinical data to suggest that nonandrogen signals can also affect folliculosebaceous unit, especially in women. discovery oestrogen receptor beta renewed redefined prior concepts activity signalling biology. It postulated oestrogens modulate growth their influence on other hormones,...

10.1111/j.1365-2133.2011.10629.x article EN British Journal of Dermatology 2011-12-01

Abstract Obesity in children is a major public health concern the U nited S tates. The objectives of current study were to determine prevalence various groups cutaneous disorders obese and adolescents compare use dermatology services subjects with that those normal body mass index ( BMI ). This was retrospective, population‐based at K aiser P ermanente N orthern C alifornia M anaged H ealthcare ystem. main outcome measures relative risk associated insulin resistance, androgen excess,...

10.1111/pde.12271 article EN Pediatric Dermatology 2013-12-13
Coming Soon ...